Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pervasive Developmental Disorder NOS Clear all
Completed Phase 2 Interventional Results available

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592786
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
72
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

Atomoxetine, Placebo and Parent Management Training in Autism

NCT00844753
View directory record Official record
Conditions
Autism, Pervasive Development Disorder, Asperger's Disorder, Attention Deficit Hyperactivity Disorder
Interventions
atomoxetine, Placebo, Parent Management Training
Drug · Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
5 Years to 14 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Rochester, New York • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 2 Interventional

A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.

NCT00198055
View directory record Official record
Conditions
Asperger's Disorder, Pervasive Developmental Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 1Phase 2 Interventional

Cholesterol in ASD: Characterization and Treatment

NCT00965068
View directory record Official record
Conditions
Autism, Asperger Disorder, PDD-NOS
Interventions
Cholesterol
Other
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
4 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 23, 2026, 3:02 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Mitochondrial Dysfunction in Autism Spectrum Disorder

NCT02000284
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, Mitochondrial Disease, Developmental Delay
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
0 Years to 17 Years
Enrollment
297 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 23, 2026, 3:02 PM EDT
Not listed Phase 4 Interventional

An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum

NCT02199925
View directory record Official record
Conditions
Autism, Autistic Disorder, Asperger's Disorder, PDD, Pervasive Developmental Disorder
Interventions
Gammaplex 5%
Drug
Lead sponsor
Isaac Melamed
Industry
Eligibility
4 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavior Therapy for Irritability in Autism

NCT04654260
View directory record Official record
Conditions
Autism Spectrum Disorder, Irritability, Disruptive Behavior, Anger, Aggression, Asperger Syndrome, Pervasive Developmental Disorder
Interventions
Behavioral Therapy for Irritability in Autism, Psychoeducation and Supportive Therapy (PST)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
12 Years to 19 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders

NCT00308074
View directory record Official record
Conditions
Autism, Asperger's Disorder, Pervasive Developmental Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
6 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Jul 23, 2026, 3:02 PM EDT
Withdrawn Phase 2 Interventional

Mercury Chelation to Treat Autism

NCT00376194
View directory record Official record
Conditions
Autism, Asperger's Disorder, Child Development Disorders, Pervasive
Interventions
DMSA
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
4 Years to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Jul 23, 2026, 3:02 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592773
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
68
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders

NCT00453180
View directory record Official record
Conditions
Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
4 Years to 12 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 23, 2026, 3:02 PM EDT
Recruiting Phase 2 Interventional

The Impact of a Virtual Magic Trick Training Program

NCT05664841
View directory record Official record
Conditions
Autism, Pervasive Developmental Disorder
Interventions
magic trick training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
11 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Results available

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

NCT03569631
View directory record Official record
Conditions
Fragile X Syndrome, FXS, Fra(X) Syndrome
Interventions
BPN14770, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 1 Interventional

Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders

NCT00773812
View directory record Official record
Conditions
Autistic Disorder, Pervasive Developmental Disorder
Interventions
mecamylamine, placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 23, 2026, 3:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

NCT00579267
View directory record Official record
Conditions
Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions
MINI-KID
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2009 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 2 Interventional

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

NCT00086645
View directory record Official record
Conditions
Autistic Disorder
Interventions
citalopram hydrobromide, placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
5 Years to 17 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Lebanon, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

NCT00709202
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Betahistine, Placebo Oral Tablet
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 3 Interventional

Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.

NCT00399698
View directory record Official record
Conditions
Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit/Hyperactivity Disorder (ADHD), Intermittent Explosive Disorder, Impulse-Control Disorders, Adjustment Disorder, Bipolar Disorder, Pervasive Developmental Disorder
Interventions
Risperdal
Drug
Lead sponsor
Ohio State University
Other
Eligibility
4 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Results available

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

NCT01731119
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions
Latuda©
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Psychotherapy for Anxiety in Children With Autism Spectrum Disorder

NCT02028247
View directory record Official record
Conditions
Autism Spectrum Disorders, Autism, Asperger's Syndrome, Pervasive Developmental Disability - Not Otherwise Specified, Obsessive-compulsive Disorder, Social Phobia, Generalized Anxiety Disorder, Specific Phobia, Separation Anxiety Disorder
Interventions
Personalized Cognitive-behavioral therapy, Standard Practice Cognitive-behavioral therapy, Treatment as Usual
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
7 Years to 13 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Jul 23, 2026, 3:02 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies

NCT01553240
View directory record Official record
Conditions
Autism Spectrum Disorder, Asperger Disorder, Pervasive Developmental Disorder
Interventions
TMS and functional MRI (Magstim)
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 23, 2026, 3:02 PM EDT
Terminated Not applicable Interventional Results available

Memantine in Adult Autism Spectrum Disorder

NCT01078844
View directory record Official record
Conditions
Autism, Asperger's Disorder, Pervasive Developmental Disorder NOS
Interventions
memantine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jul 23, 2026, 3:02 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

EEG Studies of Sensory Processing in Autistic Children

NCT00319722
View directory record Official record
Conditions
Autism
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Months to 8 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Jul 23, 2026, 3:02 PM EDT